suspension 1
hit 1
drug 1
by 1
Shares 1
MS 1
suspension 1
hit 1
drug 1
by 1
Shares 1
MS 1
the 2
in 2
drug 2
Shares 2
suspension 1
suspended 1
sclerosis 1
sales 1
plunged 1
patient's 1
on 1
of 1
new 1
multiple 1
hit 1
firms 1
death 1
by 1
as 1
and 1
after 1
a 1
US. 1
Tysabri 1
Monday 1
MS 1
Idec 1
Elan 1
Biogen 1
the 2
in 2
drug 2
Shares 2
suspension 1
suspended 1
sclerosis 1
sales 1
plunged 1
patient's 1
on 1
of 1
new 1
multiple 1
hit 1
firms 1
death 1
by 1
as 1
and 1
after 1
a 1
US. 1
Tysabri 1
Monday 1
MS 1
Idec 1
Elan 1
Biogen 1
the 9
in 5
of 4
and 4
Tysabri 4
sclerosis 3
multiple 3
a 3
The 3
Biogen 3
was 2
use 2
firms 2
drug 2
death 2
after 2
US 2
Shares 2
Idec 2
Elan 2
- 2
world's 1
widely 1
while 1
treatment. 1
took 1
to 1
tipped 1
they 1
taking 1
system 1
suspension 1
suspended 1
suspected 1
shed 1
shares 1
sales 1
said 1
reports 1
rare 1
progressive 1
plunged 1
patients 1
patient's 1
partner 1
or 1
on 1
no 1
new 1
nervous 1
multifocal 1
lost 1
leukoencephalopathy 1
leading 1
last 1
involved 1
hit 1
have 1
from 1
for 1
existing 1
either 1
drug. 1
disease 1
condition. 1
condition 1
companies 1
cited 1
central 1
cases 1
case 1
by 1
both 1
become 1
as 1
approved 1
alone. 1
action 1
York 1
US. 1
Stock 1
On 1
November 1
New 1
Monday 1
MS 1
Ireland-based 1
Idec's 1
Exchange, 1
Avonex, 1
Avonex 1
70% 1
43%. 1
(PML) 1
the 9
in 5
of 4
and 4
Tysabri 4
sclerosis 3
multiple 3
a 3
The 3
Biogen 3
was 2
use 2
firms 2
drug 2
death 2
after 2
US 2
Shares 2
Idec 2
Elan 2
- 2
world's 1
widely 1
while 1
treatment. 1
took 1
to 1
tipped 1
they 1
taking 1
system 1
suspension 1
suspended 1
suspected 1
shed 1
shares 1
sales 1
said 1
reports 1
rare 1
progressive 1
plunged 1
patients 1
patient's 1
partner 1
or 1
on 1
no 1
new 1
nervous 1
multifocal 1
lost 1
leukoencephalopathy 1
leading 1
last 1
involved 1
hit 1
have 1
from 1
for 1
existing 1
either 1
drug. 1
disease 1
condition. 1
condition 1
companies 1
cited 1
central 1
cases 1
case 1
by 1
both 1
become 1
as 1
approved 1
alone. 1
action 1
York 1
US. 1
Stock 1
On 1
November 1
New 1
Monday 1
MS 1
Ireland-based 1
Idec's 1
Exchange, 1
Avonex, 1
Avonex 1
70% 1
43%. 1
(PML) 1
the 11
of 7
in 7
and 6
to 4
a 4
Tysabri 4
will 3
sclerosis 3
multiple 3
firms 3
The 3
Biogen 3
with 2
was 2
use 2
said 2
possible 2
patients 2
leading 2
drug 2
death 2
companies 2
clinical 2
after 2
US 2
Shares 2
Idec 2
Elan 2
- 2
"The 2
world's 1
work 1
widely 1
while 1
used 1
understand 1
two 1
trials 1
treatment. 1
took 1
tipped 1
they 1
these 1
taking 1
system 1
suspension 1
suspended 1
suspected 1
statement. 1
shed 1
shares 1
sales 1
risk 1
reports 1
re-initiation 1
rare 1
progressive 1
plunged 1
patient's 1
partner 1
outcome 1
or 1
on 1
no 1
new 1
nervous 1
multifocal 1
lost 1
leukoencephalopathy 1
last 1
involved 1
investigators 1
hit 1
have 1
future 1
from 1
for 1
experts 1
existing 1
evaluations 1
evaluate 1
either 1
drug. 1
dosing 1
disease 1
determine 1
consult 1
condition. 1
condition 1
commercial 1
cited 1
central 1
cases 1
case 1
by 1
both 1
better 1
become 1
be 1
availability." 1
as 1
approved 1
alone. 1
action 1
York 1
US. 1
Tysabri-treated 1
Stock 1
PML," 1
On 1
November 1
New 1
Monday 1
MS 1
Ireland-based 1
Idec's 1
Exchange, 1
Avonex, 1
Avonex 1
70% 1
43%. 1
(PML) 1
the 11
of 7
in 7
and 6
to 4
a 4
Tysabri 4
will 3
sclerosis 3
multiple 3
firms 3
The 3
Biogen 3
with 2
was 2
use 2
said 2
possible 2
patients 2
leading 2
drug 2
death 2
companies 2
clinical 2
after 2
US 2
Shares 2
Idec 2
Elan 2
- 2
"The 2
world's 1
work 1
widely 1
while 1
used 1
understand 1
two 1
trials 1
treatment. 1
took 1
tipped 1
they 1
these 1
taking 1
system 1
suspension 1
suspended 1
suspected 1
statement. 1
shed 1
shares 1
sales 1
risk 1
reports 1
re-initiation 1
rare 1
progressive 1
plunged 1
patient's 1
partner 1
outcome 1
or 1
on 1
no 1
new 1
nervous 1
multifocal 1
lost 1
leukoencephalopathy 1
last 1
involved 1
investigators 1
hit 1
have 1
future 1
from 1
for 1
experts 1
existing 1
evaluations 1
evaluate 1
either 1
drug. 1
dosing 1
disease 1
determine 1
consult 1
condition. 1
condition 1
commercial 1
cited 1
central 1
cases 1
case 1
by 1
both 1
better 1
become 1
be 1
availability." 1
as 1
approved 1
alone. 1
action 1
York 1
US. 1
Tysabri-treated 1
Stock 1
PML," 1
On 1
November 1
New 1
Monday 1
MS 1
Ireland-based 1
Idec's 1
Exchange, 1
Avonex, 1
Avonex 1
70% 1
43%. 1
(PML) 1
the 19
in 11
to 8
of 8
a 7
and 6
Biogen 5
was 4
Tysabri 4
with 3
will 3
sclerosis 3
said 3
new 3
multiple 3
from 3
firms 3
The 3
Elan 3
while 2
use 2
possible 2
patients 2
on 2
leading 2
last 2
had 2
for 2
firm 2
drug 2
death 2
companies 2
clinical 2
by 2
at 2
after 2
US 2
Shares 2
Idec 2
- 2
"The 2
year. 1
would 1
world's 1
work 1
widely 1
which 1
value 1
used 1
understand 1
two 1
trials 1
treatment. 1
took 1
tipped 1
they 1
these 1
there's 1
taking 1
system 1
suspension 1
suspended 1
suspected 1
stock 1
statement. 1
since, 1
shed 1
shares 1
share 1
sales 1
rivals 1
risk 1
reports 1
receive 1
rebuilding 1
re-initiation 1
rare 1
question 1
provide 1
progressive 1
product. 1
product 1
price 1
plunged 1
patient's 1
partner 1
over 1
outcome 1
or 1
opportunity 1
once 1
no 1
nervous 1
multifocal 1
mark 1
lost 1
leukoencephalopathy 1
itself 1
its 1
it." 1
involved 1
investigators 1
into 1
inquiry 1
increasing 1
increased 1
hit 1
have 1
has 1
growth 1
group 1
future 1
four-fold 1
finished 1
fell 1
faced 1
experts 1
expected 1
existing 1
exchange, 1
evaluations 1
evaluate 1
either 1
drug. 1
down 1
dosing 1
disease 1
determine 1
consult 1
condition. 1
condition 1
competition 1
company 1
commercial 1
close 1
cited 1
central 1
cases 1
case 1
but 1
brought 1
both 1
boost, 1
biggest 1
better 1
believed 1
been 1
become 1
be 1
bankruptcy 1
availability." 1
as 1
approved 1
also 1
alone. 1
almost 1
action 1
accounts 1
York 1
US. 1
Tysabri-treated 1
Tysabri," 1
Stockbrokers 1
Stock 1
PML," 1
On 1
November 1
New 1
Monday 1
MS 1
Irish 1
Ireland-based 1
Idec, 1
Idec's 1
Ian 1
Hunter 1
Goodbody 1
Exchange, 1
Elan, 1
Elan's 1
Dublin. 1
Avonex. 1
Avonex, 1
Avonex 1
Analysts 1
An 1
70% 1
43%. 1
2002 1
(PML) 1
$8, 1
$38.65. 1
$28.63 1
$18.90 1
"Now 1
"Most 1
the 19
in 11
to 8
of 8
a 7
and 6
Biogen 5
was 4
Tysabri 4
with 3
will 3
sclerosis 3
said 3
new 3
multiple 3
from 3
firms 3
The 3
Elan 3
while 2
use 2
possible 2
patients 2
on 2
leading 2
last 2
had 2
for 2
firm 2
drug 2
death 2
companies 2
clinical 2
by 2
at 2
after 2
US 2
Shares 2
Idec 2
- 2
"The 2
year. 1
would 1
world's 1
work 1
widely 1
which 1
value 1
used 1
understand 1
two 1
trials 1
treatment. 1
took 1
tipped 1
they 1
these 1
there's 1
taking 1
system 1
suspension 1
suspended 1
suspected 1
stock 1
statement. 1
since, 1
shed 1
shares 1
share 1
sales 1
rivals 1
risk 1
reports 1
receive 1
rebuilding 1
re-initiation 1
rare 1
question 1
provide 1
progressive 1
product. 1
product 1
price 1
plunged 1
patient's 1
partner 1
over 1
outcome 1
or 1
opportunity 1
once 1
no 1
nervous 1
multifocal 1
mark 1
lost 1
leukoencephalopathy 1
itself 1
its 1
it." 1
involved 1
investigators 1
into 1
inquiry 1
increasing 1
increased 1
hit 1
have 1
has 1
growth 1
group 1
future 1
four-fold 1
finished 1
fell 1
faced 1
experts 1
expected 1
existing 1
exchange, 1
evaluations 1
evaluate 1
either 1
drug. 1
down 1
dosing 1
disease 1
determine 1
consult 1
condition. 1
condition 1
competition 1
company 1
commercial 1
close 1
cited 1
central 1
cases 1
case 1
but 1
brought 1
both 1
boost, 1
biggest 1
better 1
believed 1
been 1
become 1
be 1
bankruptcy 1
availability." 1
as 1
approved 1
also 1
alone. 1
almost 1
action 1
accounts 1
York 1
US. 1
Tysabri-treated 1
Tysabri," 1
Stockbrokers 1
Stock 1
PML," 1
On 1
November 1
New 1
Monday 1
MS 1
Irish 1
Ireland-based 1
Idec, 1
Idec's 1
Ian 1
Hunter 1
Goodbody 1
Exchange, 1
Elan, 1
Elan's 1
Dublin. 1
Avonex. 1
Avonex, 1
Avonex 1
Analysts 1
An 1
70% 1
43%. 1
2002 1
(PML) 1
$8, 1
$38.65. 1
$28.63 1
$18.90 1
"Now 1
"Most 1
the 21
in 12
to 11
of 10
a 10
was 6
and 6
said 5
on 5
Biogen 5
Tysabri 4
with 3
will 3
sclerosis 3
new 3
multiple 3
from 3
firms 3
firm 3
at 3
after 3
The 3
Shares 3
Elan 3
- 3
while 2
use 2
treatment. 2
possible 2
patients 2
partner 2
over 2
leading 2
last 2
its 2
had 2
future 2
for 2
drug 2
down 2
disease 2
death 2
companies 2
clinical 2
by 2
US 2
Stock 2
Phytopharm 2
Idec 2
"The 2
year. 1
would 1
world's 1
work 1
widely 1
which 1
value 1
used 1
understand 1
two 1
trials 1
took 1
tipped 1
they 1
these 1
there's 1
taking 1
system 1
suspension 1
suspended 1
suspected 1
stock 1
statement. 1
since, 1
shed 1
shares 1
share 1
set 1
sales 1
rivals 1
risk 1
reserves. 1
reports 1
receive 1
rebuilding 1
re-initiation 1
rare 1
raise 1
questions 1
question 1
pull 1
provide 1
prompting 1
progressive 1
product. 1
product 1
price 1
plunged 1
pharmaceutical 1
pence 1
patient's 1
outcome 1
out 1
or 1
opportunity 1
once 1
no 1
nervous 1
multifocal 1
mark 1
lost 1
likely 1
licensing 1
level 1
leukoencephalopathy 1
itself 1
it." 1
it 1
involved 1
investigators 1
into 1
inquiry 1
increasing 1
increased 1
hit 1
have 1
has 1
growth 1
group 1
four-fold 1
finished 1
fell 1
faced 1
experts 1
experimental 1
expected 1
existing 1
exchange, 1
evaluations 1
evaluate 1
end 1
either 1
drug. 1
dosing 1
determine 1
deal 1
consult 1
condition. 1
condition 1
competition 1
company 1
commercial 1
closed 1
close 1
cited 1
central 1
cash 1
cases 1
case 1
but 1
brought 1
both 1
boost, 1
biggest 1
better 1
believed 1
been 1
become 1
be 1
bankruptcy 1
availability." 1
as 1
approved 1
analysts 1
an 1
also 1
alone. 1
almost 1
agreement, 1
action 1
accounts 1
York 1
Yamanouchi 1
US. 1
UK 1
Tysabri-treated 1
Tysabri," 1
Stockbrokers 1
Pharmaceutical 1
PML," 1
On 1
November 1
New 1
Monday, 1
Monday 1
MS 1
London 1
Japan's 1
Irish 1
Ireland-based 1
Idec, 1
Idec's 1
Ian 1
Hunter 1
Goodbody 1
Exchange, 1
Exchange 1
Elan, 1
Elan's 1
Dublin. 1
Avonex. 1
Avonex, 1
Avonex 1
Analysts 1
An 1
Alzheimer's 1
70% 1
43%. 1
2002 1
19.84% 1
151.5 1
(PML) 1
$8, 1
$38.65. 1
$28.63 1
$18.90 1
"Now 1
"Most 1
